CTLA4 and melanoma: Our initial results were entirely consistent with and extended such findings in that we were able to observe an astonishing anti-tumor resistance in hard-to-treat mouse models such as the anti-CTLA-4- and anti-PD-1-refractory YUMM1.7 mouse melanoma.